Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2012

View Archived Issues

New MMP inhibitors designed

Scientists in Germany patent novel HSP 90 inhibitors

Merck & Co. prepares novel HCV inhibitors

New transient receptor potential TRPM8 channel antagonists patented

Novel phosphodiesterase 10A inhibitors presented by Merck & Co.

Novel histamine H4 receptor ligands designed in France

Enanta presents novel antiviral with excellent cross-resistance profile

New Roche oncolytic targets chondroitin sulfate proteoglycan 4

BAF-312 dose titration reduces bradyarrhythmic events in phase II trial

Phase I data encourage advancement of candidate MS drug to phase II

MicroDose Therapeutx completes phase I studies of MDT-637

Omontys launched in U.S.

Alimera announces first marketing authorization for Iluvien in E.U.

Bayer expands BiTE antibody collaboration

Recruitment complete in phase II studies of Levulan Kerastick PDT

New Presidio product shows promise to treat hepatitis

Nordion plans new phase III TheraSphere trial

Summit clear to conduct phase I trial of SMT-C1100

Adocia reports phase II results for diabetic foot ulcer treatment

Nanobody for Alzheimer's disease advances toward phase I trials

NICE issues final guidance on new hepatitis C drugs

Recommendations issued for treatment of first-line chronic myeloid leukemia

NICE recommends NHS provide Gilenya in relapsing-remitting MS

Hisamitsu reports on HTU-520 study

First medicine approved in E.U. for Cushing's disease

Popular Stories

University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Beijing Innocare Pharma Tech discloses new GSPT1 degradation inducers
BioWorld Science
Beijing Innocare Pharma Tech Co. Ltd. has synthesized new antibody-drug conjugates comprising antibody or antigen-binding fragment covalently linked to eukaryotic...